Medical Technology Association of India, which represents leading research-based medical technology companies with significant investments in India, today said that the government’s move to set up specialist committees to review package rates for more than 1300 health procedures under AB-PMJAY gives a chance to correct the currently low and unviable rates for several procedures.
“Setting up of committees to evaluate the current package rates under AB-PMJAY is a step in the right direction. However, we hope for inclusion of all stakeholders in these crucial decisions to adequately address all concerns. The current AB-PMJAY procedure rates are quite low. For several procedures, the rates are even lower than those of CGHS, making them unviable. It has been a long-standing request from hospitals as well as the MedTech industry for revision of these rates,” said Pavan Choudary, Chairman and Director General, MTaI.
“Unlike CGHS, the cost of medical device is subsumed in AB-PMJAY package cost. The industry looks forward to this re-evaluation exercise and hopes that the government will consider segregating the device cost from the procedure cost to ensure that the basic minimum quality of devices is maintained”, he added.
“We also urge the government to promote patient choice and access by allowing them to top-up, if they wish to upgrade and go for a higher quality of device or procedure,” he concluded.
This story is provided by NewsVoir. ANI will not be responsible in any way for the content of this article.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
